Amlodipine + Olmesartan Medoxomil
Therapeutic Class: Combined antihypertensive preparations
Indications:
Amlodipine & Olmesartan is indicated for the treatment of hypertension, alone or with other antihypertensive agents. this might even be used as initial therapy in patients who are likely to wish multiple antihypertensive agents to realize their vital sign goals.
Pharmacology:
Amlodipine may be a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle & heart muscle. Amlodipine may be a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a discount in peripheral vascular resistance & a discount in vital signs.
Olmesartan is an angiotensin II receptor blocker that acts on the AT1 subtype. By blocking the action of angiotensin II, Olmesartan dilates blood vessels and reduces vital signs without affecting pulse.
Dosage & Administration:
Initial Therapy: the standard starting dose of Amlodipine & Olmesartanis one tablet (5/20 mg) once daily. The dosage is often increased after 1 to 2 weeks of therapy to a maximum dose is 2 tablets (10/40 mg) once daily as required to regulate vital sign. this might be crazy or without food and should be administered with other antihypertensive agents. Initial therapy with this mixed product isn't recommended in patients ≥75 years old or with hepatic impairment.
Replacement Therapy: Amlodipine & Olmesartanmay be substituted for its individually titrated components. When substituting for individual components, the dose of 1 or both of the components is often increased if vital sign control has not been satisfactory.
Add-on Therapy: Amlodipine & Olmesartanmay be wont to provide additional vital sign lowering for patients not adequately controlled with Amlodipine (or another dihydropyridine calcium channel blocker) alone or with Olmesartan Medoxomil (or another angiotensin II receptor blocker) alone.
Interaction:
The pharmacokinetics of Amlodipine and Olmesartan Medoxomil isn't altered when the drugs are co-administered. No drug interaction studies are conducted with Amlodipine and Olmesartan combination tablet and other drugs, although studies are conducted with the individual Amlodipine and Olmesartan Medoxomil components, and no significant drug interactions are observed.
Contraindications:
Hypersensitivity to any of the components of this mixed product.
Side Effects:
The reported adverse reactions were generally mild and rarely led to discontinuation of treatment. the foremost common side effects include edema, dizziness, flushing, palpitation. Other side effects may include vomiting, diarrhea, rhabdomyolysis, alopecia, pruritus, urticaria, etc.
Pregnancy & Lactation:
Pregnancy: When pregnancy is detected, discontinue this mixed product as soon as possible. When utilized in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.
Nursing Mothers: due to the potential for adverse effects on the nursing infant, a choice should be made whether to discontinue nursing or discontinue the drug, taking under consideration the importance of the drug to the mother.
Precautions & Warnings:
Fetal/Neonatal Morbidity and Mortality: When pregnancy is detected, this mix should be discontinued as soon as possible.
Hypotension in Volume or Salt Depleted Patients: Symptomatic hypotension may occur after initiation of treatment.
Vasodilatation: Caution should be exercised when administering the drug, particularly in patients with severe stenosis.
Patients with Severe Obstructive arteria coronaria Disease: Patients may develop increased frequency, duration, or severity of angina or acute myocardial infarct on starting calcium channel blocker therapy or at the time of dosage increase.
Patients with Congestive Heart Failure: Calcium channel blockers should be used with caution in patients with coronary failure.
Patients with Impaired Renal Function: Caution should be exercised when administering the drug to patients with renal impairment.
Patients with Hepatic Impairment: Caution should be exercised when administering the drug to patients with severe hepatic impairment.
Overdose Effects:
There is no experience of overdose with the Amlodipine & Olmesartan combination. the foremost likely effects of olmesartan medoxomil overdosage are hypotension and tachycardia; bradycardia might be encountered if parasympathetic (vagal) stimulation occurred.
Amlodipine overdosage is often expected to steer to excessive peripheral vasodilatation with marked hypotension and possibly a reflex tachycardia. Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome has been reported.
Storage:
Keep out of the reach of children. Store below 30°C. confine the first package during a cool & dry place so as to guard against light and moisture.
0 Comments
if you have any doudts.please let me know